SpyGlass Pharma closes $172.5mln IPO, underwriters exercise option in full.

SpyGlass Pharma has completed its initial public offering (IPO) with the sale of 10.78 million shares at $16.00 per share, raising $172.5 million before underwriting discounts and expenses. The underwriters exercised their option to purchase an additional 1.4 million shares, bringing the total number of shares sold to 12.2 million. The IPO marks SpyGlass Pharma's debut on the Nasdaq Global Select Market.